A Safety and Tolerability Study of FCN-207 in Healthy Volunteers

NCT04622124 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2024-08-05

No results posted yet for this study

Summary

This research study is studying an investigational drug called FCN-207 in healthy adult males or females.

Conditions

  • Hyperuricemia

Interventions

DRUG

Placebo

DIETARY_SUPPLEMENT

fasted vs. high-fat meal

DRUG

Placebo

Sponsors & Collaborators

  • Fochon Pharmaceuticals, Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-11
Primary Completion
2021-12-21
Completion
2022-06-07

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04622124 on ClinicalTrials.gov